Lead Product(s) : Amylin
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Skandinaviska Enskilda Banken
Deal Size : $71.6 million
Deal Type : Public Offering
Details : The net proceeds are expected to be used for geographic expansion of the contract research activities, continued development of the drug candidate pipeline including amylin for the treatment of obesity, technological solutions and proprietary platforms a...
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 06, 2023
Lead Product(s) : Amylin
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Skandinaviska Enskilda Banken
Deal Size : $71.6 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?
Reset All
